Catalyst Wire Dossier Catalyst Wire Dossier

IG-002 (oral levonorgestrel plus meloxicam)

levonorgestrel; meloxicam · InnovaGyn, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IG-002 (oral levonorgestrel plus meloxicam), covering 2026-06-17 to 2026-06-17. Get the full timeline:

Most recent: Clinical Trial Results: Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days [Phase 2]

See pricing